QUANTIFICATION OF THE hsa-miR-30c-5/VIM, hsa-miR-28-3p/VIM, hsa-miR-1-3p/ANXA2, hsa-miR-30c-5p/FBN1, hsa-miR-15b-5p/MYL6 tr.v.1, hsa-miR-15b-5p/MYL6 tr.v.2, hsa-miR-185-3p/FLNA, hsa-miR-1-3p/YWHAZ, hsa-miR-30c-5p/YWHAZ AND hsa-miR-654-3p/FGA RATIO IN THE PLACENTAL SITE OF WOMEN ON THE DAY OF DELIVERY AT A TERM OF MORE THAN 34 WEEKS OF GESTATION AS A METHOD FOR DIFFERENTIAL DIAGNOSIS OF FETAL GROWTH RESTRICTION SYNDROME, PREECLAMPSIA AND A SMALL FOR GESTATIONAL AGE FETUS SYNDROME Russian patent published in 2022 - IPC G01N33/58 C12Q1/6806 C12Q1/6851 C12Q1/686 C12Q1/6876 

FIELD: medicine.

SUBSTANCE: invention relates to the field of biomedicine, in particular, to obstetrics and molecular biology, and is intended for differential diagnosis of fetal growth restriction syndrome (FGR), preeclampsia (PE), and a small for gestational age fetus syndrome. The hsa-miR-30c-5p/VIM, hsa-miR-28-3p/VIM, hsa-miR-1-3p/ANXA2, hsa-miR-30c-5p/FBN1, hsa-miR-15b-5p/MYL6 tr.v.1, hsa-miR-15b-5p/MYL6 tr.v.2, hsa-miR-185-3p/FLNA, hsa-miR-1-3p/YWHAZ, hsa-miR-30c-5p/YWHAZ and hsa-miR-654-3p/FGA ratio is quantified in the placental site of women on the day of delivery at a term of more than 34 weeks of gestation. Logarithms of the values of said ratios to base two are calculated. Based on the above calculation, FGR, PE and the small for gestational age fetus syndrome are differentiated.

EFFECT: invention ensures verification of the diagnosis made on the basis of clinical and laboratory research methods on the day of delivery to select the optimal management tactics for the mother and the child for the purpose of preventing possible postpartum complications.

1 cl, 1 dwg, 4 tbl, 1 ex